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Abstract 
Differentiating actions of Short Chain Fatty Acids (SCFAs) at Free Fatty Acid receptor 2 
(FFA2) from other free fatty acid-responsive receptors, and from non-receptor mediated 
effects, has been challenging. Using a novel chemogenetic and knockin strategy whereby an 
engineered variant of FFA2 (FFA2-DREADD) that is unresponsive to natural SCFAs but 
instead is activated by sorbic acid replaced the wild type receptor we determined that 
activation of FFA2 in differentiated adipocytes and colonic crypt enteroendocrine cells of 
mouse accounts fully for SCFA-regulated lipolysis and release of the incretin glucagon like 
peptide-1 (GLP-1) respectively. In vivo studies confirmed the specific role of FFA2 in GLP-1 
release and also demonstrated a direct role for FFA2 in accelerating gut transit. Thereby we 
establish the general principle that such a chemogenetic knockin strategy can successfully 
define novel GPCR biology and both provide target validation and establish therapeutic 
potential of a ‘hard to target’ GPCR.  
 
Introduction 
The health benefits of a balanced diet rich in fibre are well established, however 
understanding of mechanisms underlying these benefits has only recently come to light with 
appreciation of the relationship between ingested food, the gut microbiome and health and 
well-being1. In the case of dietary fibre, fermentation of poorly digested carbohydrates by the 
gut microbiota produces prodigious amounts of SCFAs, particularly acetate and propionate2. 
These SCFAs, in addition to acting as an energy source, also have direct biological activities 
by acting in a hormone-like fashion through specific G protein-coupled receptors (GPCRs)3-5. 
The physiological roles of the two best characterised SCFA-activated GPCRs, FFA2 and 
FFA3 (previously known as GPR41 and GPR43 3), however  are challenging to define as the 
potency of SCFAs is both low and similar between these two subtypes. Moreover, 
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pharmacological tools for these receptors are limited and not broadly available6-7 and the only 
described FFA2 antagonists are ‘human specific’ and not effective at rodent orthologues6-8. 
Despite this, there is great interest in the potential therapeutic utility of targeting this receptor 
class and the FFA2 antagonist GLPG0974 ((4-[[1-(benzo[b]thiophene-3-carbonyl)-2-
methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid) has been assessed in ‘first-
in-man’ studies designed to treat ulcerative colitis9.  
To address the physiological role of FFA2 we have adopted a chemogenetic approach 
pioneered largely using muscarinic acetylcholine receptors. In this approach mutations in the 
orthosteric binding site are introduced that prevent receptor activation by endogenous 
agonists but instead allows for activation by otherwise inert chemical ligands. Such mutant 
receptors, called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) 
have been widely used to probe signalling pathways that underlie both central and peripheral 
responses10-15. Here we have taken an alternative approach employing a novel FFA2-
DREADD16 knocked into the gene locus of the wild type receptor to generate a strain of mice 
that would mimic an FFA2-receptor knockout strain because the DREADD receptor is 
predicted to be unresponsive to endogenous SCFAs. However, unlike a gene knockout, 
phenotypic and functional deficits observed in the FFA2-DREADD-knockin mice should, 
theoretically, be rescued by a FFA2-DREADD specific ligand, in this case sorbic acid (SA), 
which exclusively activates the DREADD receptor16.  
Previously we generated a DREADD variant of human (h) FFA216 by substitution of 
two amino acids, located in the 4th and 6th transmembrane regions (Cys4.57Gly and 
His6.55Gln, position numbers as defined by the Ballesteros and Weinstein numbering 
system17). In so doing we took advantage of the observed variation in the chain length of fatty 
acids that act as agonists at certain species orthologues of FFA2 and linked this with 
homology modelling and mutagenesis to infer potentially important roles for these two 
 5 
residues16. The hFFA2-DREADD variant no longer responded effectively to the SCFAs 
acetate and propionate but, rather, could be activated by a number of other ligands, including 
SA, which had no effect at the wild type receptor, nor at FFA316. Importantly, the hFFA2-
DREADD was not only activated by SA but, as shown here, is antagonised effectively by a 
pair of chemically distinct, human orthologue specific, FFA2 antagonists8, 18-20.  
By employing these tools here we tested the hypothesis that a DREADD-knockin 
mouse strain would induce phenotypic deficits that mimicked a knockout strain and that this 
deficit might be rescued by a DREADD ligand. Furthermore, we tested if the DREADD 
ligand response might be blocked by antagonists that are only active at the species orthologue 
from which the DREADD was derived. Thus, we report here that by using FFA2 as an 
exemplar receptor we were able to employ hFFA2-DREADD to probe the physiological role 
of FFA2 in the gut and white adipose tissue and also provide evidence for the general 
principle that employing DREADD-knockin mice can be an effective strategy to probe the 
function and therapeutic potential of ‘hard to target’ GPCRs.  
 
Results 
Properties of hFFA2-DREADD 
Early studies on hFFA2 suggested that this receptor is able to interact, at least in vitro, 
with a broad range of G proteins21. We compared, therefore, the ability of propionate (C3) 
and SA to promote interactions of either wild type hFFA2 or hFFA2-DREADD across the 
range of mammalian G protein  subunits. Initially we employed a bioluminescence 
resonance energy transfer (BRET)-based biosensor strategy that reports on agonist-induced 
interactions between a Renilla luciferase (Rluc)-tagged form of the G protein-coupled 
receptor kinase (GRK)2 and a G protein  complex containing a GFP10-tagged form of the 
5 subunit22. This biosensor is based on the competition between G and GRK2 for 
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interaction with G upon over-expression of each individual unlabeled G subunit. The 
separation of G from the G subunit upon receptor activation produces an increase in 
BRET between GRK2-GFP10 and RlucII-Gγ5. Following co-transfection of HEK293 cells 
expressing the BRET biosensors with either hFFA2 or hFFA2-DREADD and each of thirteen 
distinct G protein  subunits addition of C3 to cells expressing hFFA2 resulted in enhanced 
BRET signal in the presence of all the G protein  subunits tested, except for Gs (Figure 
1a). The magnitude of the enhanced BRET signal varied between individual G protein  
subunits but the wide-ranging capacity of hFFA2 to interact with different G proteins 
confirmed that agonist-activated hFFA2 can be pleiotropic in activation of G protein subtypes 
8,21. In cells expressing hFFA2-DREADD addition of SA resulted in an entirely equivalent 
profile of G protein interaction capacity and selectivity (Figure 1b). Thus, despite 
engineering the orthosteric binding site to generate a DREADD variant receptor this did not 
result in altered canonical, G protein-mediated signal transduction potential in response to the 
DREADD specific agonist. These studies established that, when acting at the hFFA2-
DREADD receptor, SA is able to produce the same and full panoply of G protein interactions 
as when C3 binds  to wild type FFA2.  
To extend these comparisons we employed a second set of biosensors that instead 
directly sense separation induced by receptor activation between a G protein  subunit tagged 
with Renilla luciferase and the G protein 1 subunit tagged with the fluorescent protein 
GFP10. When co-expressed alongside wild type hFFA2, C3 promoted a reduction in BRET 
signal for the  subunit of each of Gq, Gi1, and G13, but once again not for Gs 
(Supplementary Figure 1a). The same was true for SA when this sensor pairing was co-
expressed with hFFA2-DREADD (Supplementary Figure 1b). Parallel studies using the M3 
muscarinic acetylcholine receptor showed the agonist carbachol to cause activation of only 
Gq (Supplementary Figure 1c) and indicated that the broad range of G proteins activated by 
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the hFFA2 and hFFA2-DREADD receptors is not an artefact related to the assay biosensors 
employed. 
We next investigated the signalling of these receptors specifically through Gi and 
Gq/11 respectively in cAMP and inositol monophosphate regulation assays that reflect directly 
activation of these G proteins (Figures 1 c-f). As expected, at hFFA2 inhibition of cAMP and 
accumulation of inositol monophosphates was effectively induced by the endogenous SCFA 
C3 whereas SA showed essentially no activity (Figures 1 c, e). In contrast, at hFFA2-
DREADD SA produced potent regulation of both cAMP and inositol monophosphates 
whereas C3 was at least 1000 fold less potent  (Figures 1d, f).  
In addition to signalling through heterotrimeric G proteins hFFA2 can recruit arrestin 
adaptor proteins23-24. C3, but not SA, was able to promote interactions between wild type 
hFFA2 and β-arrestin-2 in a concentration-dependent manner (Supplementary Figure 2a), 
whilst the opposite pattern of ligand-induced engagement was observed for interactions 
between hFFA2-DREADD and β-arrestin-2 (Supplementary Figure 2b). These studies 
markedly expanded the previously reported high selectivity of SA for hFFA2-DREADD and 
lack of activity of this ligand at wild type hFFA216. 
 
hFFA2 antagonists inhibit hFFA2-DREADD activity 
Two classes of high affinity synthetic FFA2 antagonists have been described6-7. 
Exemplars from both series, including CATPB ((S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-
(trifluoromethyl)phenyl)butanoic acid) 18 and GLPG0974 20 display high affinity at hFFA2 
but not at rodent orthologues of FFA2 6-8. Here we assessed whether the ability of both 
CATPB and GLPG0974 to block wild type hFFA2 was preserved for hFFA2-DREADD. 
hFFA2 binds [3H]GLPG0974 with high affinity (Kd = 7.5 nM)
19 and hFFA2-DREADD 
bound [3H]GLPG0974 with similar high affinity (Kd = 2.2 ± 0.16 nM) (Supplementary 
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Figure 3a). Competition binding experiments against [3H]GLPG0974 confirmed both 
GLPG0974 and CATPB interacted with similar affinities (pKi) at each of wild type hFFA2 
and hFFA2-DREADD (Supplementary Figures 3b, c, Supplementary Table 1). Both 
antagonists were also able to inhibit, in a concentration-dependent fashion, recruitment of β-
arrestin-2 to the appropriate receptor variants induced by EC80 concentrations of either C3 or 
SA (Supplementary Figures 3d, e, Supplementary Table 1). 
 
Generation and characterisation of hFFA2-DREADD-HA mice  
CRE-loxP technology was next employed to generate transgenic knockin mouse lines 
in which a section of exon 5 of the Ffar2 gene, containing the coding sequence for the mouse 
receptor, was replaced by sequences encoding for hFFA2-DREADD. Furthermore, a loxP-
STOP-loxP cassette was placed upstream of the receptor coding sequences whilst the 
receptor sequence was appended with an in-frame, C-terminal haemaglutinin (HA) epitope 
tag. Keeping the loxP-STOP-loxP cassette intact generated a strain that should express 
neither the wild type receptor nor the hFFA2-DREADD-HA receptor. Effectively this strain 
is an FFA2-knockout line, which we here term “MINUS-CRE”. By crossing the MINUS-
CRE strain with a whole body CRE-recombinase expressing strain, we generated mice where 
expression of hFFA2-DREADD-HA was driven from the endogenous mouse Ffar2 promoter. 
Under these conditions hFFA2-DREADD-HA receptor should be expressed in cell types and 
at levels equivalent to wild type mouse FFA2, this mouse strain is termed hFFA2-DREADD-
HA (Supplementary Figure 4; see Methods section).  
Animals were genotyped based on the presence of the inserted transgene, whilst direct 
sequencing of the transgene validated the presence of the DREADD mutations and HA-
epitope tag sequence (Methods). qRT-PCR performed using mouse FFA2 (Figure 2a) or 
hFFA2-DREADD-HA (Figure 2b) specific primers indicated that corresponding transcripts 
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showed quantitatively similar patterns of expression between wild type C57BL/6 mice and 
homozygous hFFA2-DREADD-HA expressing animals in a selection of tissues known to 
express FFA2 (white adipose tissue, colon, lung) but to be lacking in other tissues (liver and 
cortex) (Figures 2a, 2b).  Moreover,  as anticipated from the genetic design, transcripts 
corresponding to hFFA2-DREADD-HA were not detected in tissues from the MINUS-CRE 
strain of mice (Figure 2c).  Because Ffar2 and the closely related receptor gene Ffar3 are 
linked at chromosomal location 7A3, certain lines of FFA2 or FFA3 knockout mice have 
been reported to have altered expression of the other receptor25. However, we confirmed that 
mRNA encoding FFA3 was expressed equally in colonic tissue of C57BL/6,  MINUS-CRE,  
and homozygous hFFA2-DREADD-HA expressing mice (Figure 2d). 
Previous studies from our laboratory26 and others27-29 have suggested a role for FFA2 
in the release of the incretin GLP-1 from colonic crypts. Examination of the expression of 
hFFA2-DREADD-HA in the colon illustrated sparse expression within subsets of 
enteroendocrine cells of the colonic crypts (Figure 3) as determined by co-staining of the 
HA-tagged hFFA2-DREADD with chromogranin A, a broad-spectrum marker for 
enteroendocrine cells, particularly monoamine-storing enteroendocrine cells30. By contrast, 
specific HA-immunostaining was not detected in equivalent sections from either C57BL/6  
(Figure 3) or the MINUS-CRE mice (Supplementary Figure 5a). Expression of hFFA2-
DREADD-HA was also detected in a broader range of cells. For example, clusters of 
submucosal cells in the duodenum were observed that were not co-stained with chromogranin 
A, indicating that they were distinct from entroendocrine cells and likely represent 
submucosal leukocytes (Supplementary Figure 5b). Importantly, these cell clusters also 
could not be observed in equivalent sections from either C57BL/6 or the MINUS-CRE mice 
(Supplementary Figure 5b).  
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hFFA2-DREADD-HA releases GLP-1 from colonic crypts 
We next examined release of GLP-1 from isolated colonic crypt-containing 
preparations. These preparations responded to the cAMP phosphodiesterase inhibitor 
isobutylmethylxanthine (IBMX) with an approximately five-fold increase in release of GLP-
1 over basal levels (Figure 4a). The extent of IBMX response was equivalent in crypt 
preparations derived from each of C57BL/6, hFFA2-DREADD-HA and the MINUS-CRE 
mice (Figure 4a). As anticipated from previous work26, 28, C3 also promoted GLP-1 release 
from colonic crypts derived from C57BL/6 mice (Figure 4b), but SA did not (Figure 4b). By 
contrast, SA specifically promoted the release of GLP-1 from colonic crypts derived from 
hFFA2-DREADD-HA mice (Figure 4c) whilst C3 did not. Neither C3 nor SA was effective 
in preparations derived from the MINUS-CRE mouse strain (Figure 4d). These studies 
provided evidence that FFA2 mediates GLP-1 release from mouse colonic crypts. However, 
to confirm the effects of SA in tissues from the hFFA2-DREADD-HA expressing mice were 
not the result of undefined  ‘off-target’ effects of SA, we employed the structurally distinct, 
human selective, FFA2 antagonists CATPB and GLPG0974 to potentially block the effects of 
SA. Although neither CATPB nor GLPG0974 affected basal GLP-1 secretion when added 
alone (Figures 4e, 4f), both effectively blocked the release of the incretin produced by SA in 
tissue derived from hFFA2-DREADD-HA mice (Figures 4e, 4f). By contrast, no effect of 
either antagonist was observed on C3-mediated GLP-1 release from wild type C57BL/6 mice 
(Supplementary Figure 6).  
Sections of the colon from either C57BL/6 or hFFA2-DREADD-HA mice were next 
introduced into a tissue bath. Following initial flow of buffer through the lumen of the colon 
to establish baseline GLP-1 release, C3 was added to preparations from C57BL/6 mice 
(Figure 4g) whilst  SA was added to preparations from hFFA2-DREADD-HA expressing 
mice (Figure 4h).  Each agonist markedly enhanced release of GLP-1 from the expected 
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mouse line within the first sampling period and this was maintained for at least 20 minutes 
(Figures 4g,  h). For hFFA2-DREADD-HA this was clearly an ‘on-target’ FFA2-mediated 
effect of SA because pretreatment with, and the maintained presence of, GLPG0974 
completely prevented response to SA (Figure 4h). Although it can be anticipated from these 
results that the effect of C3 in colonic tissue from wild type C57BL/6 mice is also via FFA2 
this could not be be assessed directly because GLPG0974 does not have significiant affinity 
at mouse FFA2.  
 
FFA2 and the regulation of lipolysis 
To explore FFA2-mediated function in epididymal fat tissue, adipocytes were isolated 
from each of C57BL/6, hFFA2-DREADD-HA or MINUS-CRE mice, maintained in culture 
and allowed to differentiate for 8 days26. Importantly, Oil Red O staining indicated equivalent 
lipid accumulation in cells derived from each mouse strain (Figure 5a). Furthermore, the -
adrenoceptor agonist isoproterenol induced lipolysis to a similar extent and with equivalent 
potency in adipocytes derived from each strain (Figure 5b). In tests of FFA2 function 
adipocytes from C57BL/6 mice treated with C3 showed a significant reduction in 
isoproterenol-stimulated lipolysis (Figure 5c) whereas SA was without effect (Figure 5c). 
By contrast, an anti-lipolytic effect was produced by SA and not by C3 in adipocytes from 
hFFA2-DREADD-HA expressing mice (Figure 5d), whilst neither C3 nor SA was able to 
produce an anti-lipolytic effect in adipocytes derived from the MINUS-CRE line (Figure 5e). 
The effect of SA in adipocytes derived from hFFA2-DREADD-HA expressing mice was, 
moreover, concentration-dependent with pIC50 = 4.63 ± 0.18 (Supplementary Figure 7). 
Importantly, consistent with the lack of activity of the human selective antagonists CATPB 
and GLPG0974 at mouse FFA2, neither of these agents was able to block C3-mediated anti-
lipolytic effects in adipocytes derived from wild type C57BL/6 mice (Supplementary 
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Figures 8a, b). In contrast, both of these ligands, although without effect on lipolysis when 
added alone, effectively blocked the action of SA in adipocytes from hFFA2-DREADD-HA 
mice and, in each case, in a concentration-dependent manner (Figures 5f, 5g).  
To assess the contribution of different G protein sub-groups to the physiological end 
points transduced by hFFA2-DREADD-HA we pretreated isolated and cultured adipocytes 
with either pertussis toxin, which blocks Gi-mediated receptor signalling, or with FR900359 
that blocks signalling via Gq-family G proteins
26. Anti-lipolytic effects of SA were blocked 
fully by pre-treatment with pertussis toxin but unaffected by pre-treatment with FR900359 
(Supplementary Figure 9a) demonstrating this to be a Gi-mediated effect. By contrast, in 
colonic tissue SA-mediated release of GLP-1 was fully prevented by pre-treatment with 
FR900359 (Supplementary Figure 9b) whilst not affected by pertussis toxin, indicating that 
GLP-1 release is via a Gq protein. 
 
An in vivo role for FFA2 in GLP-1 release and gut transit 
To determine if SA can act on hFFA2-DREADD in vivo we adapted methods that describe 
the release of GLP-1 into the portal vein of mice following intra-colonic administered C3 31. 
We confirmed that C3 (150 mM) administered into the colon of wild type animals resulted in 
significant increase in GLP-1 plasma levels in the portal vein, a response that was completely 
absent in control MINUS-CRE mice (Figures 6a, b). Intra-colonic administration of SA 
generated a similar increase in portal vein GLP-1 plasma levels when administered to 
hFFA2-DREADD-HA mice (Figure 6c). Importantly, no response to SA was measured in  
MINUS-CRE control  animals (Figure 6b), demonstrating that in the hFFA2-DREADD-HA 
mice SA was operating via the hFFA2-DREADD receptor and that the response to SA 
mimicked the response seen for C3 at FFA2 in the wild type mice.  
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In a second test of the in vivo response of SA at hFFA2-DREADD we examined the 
potential role of FFA2 in gut transit. Previous in vivo studies had indicated that 
administration of SCFAs into the gut (gavage) accelerated gut transit 32. However, a more 
recent ex vivo study on isolated colon showed the opposite, where C3, possibly acting via 
FFA2, decreased gut transit 33.  We resolved this issue using the hFFA2-DREADD-HA mice. 
Administration of C3 in the drinking water of wild type mice accelerated gut transit whilst 
SA had no effect (Figure 6d and Supplementary Figures 10a, b, c). In contrast SA 
stimulated a significant increase in gut transit in hFFA2-DREADD-HA mice (Figure 6e and 
Supplementary Figures 10d, e).  This not only demonstrated unequivocally that SA 
activates the hFFA2-DREADD receptor in vivo but also that FFA2 activation mediates an 
increase in gut transit.   
 
Discussion 
GPCRs remain the most highly studied group of therapeutic drug targets and many 
ligands that modulate GPCR function are continuing to gain regulatory approval34. As such, 
finding novel ligands or re-purposing previously identified ones is integral to efforts to 
understand the biology and therapeutic potential, particularly of poorly studied GPCRs35-36. 
This has been approached by methods ranging from high throughput and virtual screening to 
the application of structure-based drug design. However, finding ligands that are highly 
selective between closely related GPCRs that can be used to define novel biology and in 
target validation remains a substantial challenge and a major barrier to advances in 
pharmacology and drug discovery. Here we have endeavoured to address this final issue by 
employing a DREADD receptor mutant to assess two fundamental questions; (i) can a 
DREADD mutant be utilised to distinguish the biological action of the target receptor from 
other closely related receptors (e.g. FFA2 vs FFA3) and (ii) can this approach give insights 
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into the action of selective pharmacological ligands at the target receptor in a way that can be 
used in target validation and drug design. 
Our study is a substantial departure from the more common use of DREADDs 
(particularly muscarinic acetylcholine DREADDs) which have largely been to determine the 
importance of particular down-stream signalling pathways in physiological responses12-15 and 
to link receptor activation to behavioural phenotypes37. In contrast, we have employed here a 
hFFA2-DREADD, knocked into the mouse Ffar2 gene locus in a manner that replaces the 
wild type receptor with a DREADD mutant activated by the otherwise inert synthetic 
molecule SA with the aim to define specific functions of this receptor. Such DREADD 
knockin mice have not been used before and thus were untested as a strategy to probe the 
biological function of selected target receptors.  
Importantly, we illustrate here that signalling through hFFA2-DREADD is 
indistinguishable from that of wild type hFFA2. Thus, SA promoted interactions of hFFA2-
DREADD with the same panoply of G proteins as did the SCFA, propionate, via wild type 
hFFA2. More specifically, coupling of hFFA2-DREADD to down-stream signalling 
pathways mediated by Gq and Gi family G proteins,  as well as interactions with -arrestin-2 
were equivalent to the wild type receptor. As such, activation of hFFA2-DREADD with SA 
faithfully reproduces the signalling repertoire produced by SCFAs when activating FFA2. 
This key proof-of-principle provided confidence that SA acting at hFFA2-DREADD-HA in 
tissues from knockin mice would act as an appropriate molecular probe to define biological 
roles of FFA2. Given that mFFA2 and the hFFA2-DREADD variant are able to interact with 
a wide range of G proteins, it will be interesting to explore the contribution of these to 
distinct physiological outcomes in these animals.  
Given that the hFFA2-DREADD variant displayed near equivalent signalling to the 
wild type hFFA2 receptor we proceeded to generate a knockin mouse line expressing hFFA2-
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DREADD-HA in place of wild type receptor. In this engineered line the tissue expression of 
hFFA2-DREADD-HA was the same as mFFA2 providing confidence that our model would 
faithfully reflect mFFA2 function and by inference possibly that of FFA2 in humans.   
The first expectation of hFFA2-DREADD-HA knockin mice was that responses to 
SCFAs would be lost because in vitro experiments demonstrated that this mutant receptor 
was unresponsive to SCFAs. In this way the hFFA2-DREADD-HA knockin mice were 
expected to mimic FFA2-knockout mice (represented here by the MINUS-CRE control 
strain). This indeed was proven to be the case as the previously defined anti-lipolytic 
response to the SCFA C3 in isolated adipocytes, and the induction of GLP-1 release from 
colonic crypts, was lacking in the MINUS-CRE  mice preparations. Moreover, because 
expression of FFA3 in the knockin mouse line was unaffected, the complete lack of response 
to SCFAs in these two tissue models also infers a lack of contribution of FFA3. This 
conclusion had previously been uncertain. FFA3 has been shown to be expressed by many 
enteroendocrine cells within the colon28 and these same authors suggested that a poorly 
characterised, potentially FFA3 receptor selective, activator can promote GLP-1 release28  
more effectively than activation of FFA2. Moreover, studies by Tolhurst et al.,27 had 
indicated that SCFA-mediated secretion of GLP-1 was compromised in both Ffar2 and Ffar3 
whole body knockout mice.  Our results instead show this effect to be mediated entirely by 
FFA2. As well as the stimulatory effect of the FFA2-DREADD agonist SA in tissue isolated 
from mice expressing hFFA2-DREADD-HA, this conclusion is further supported because the 
effect of SA can be defined unambiguously as being ‘on-target’ as it was completely blocked 
by exemplar compounds from two, chemically distinct, classes of human FFA2 specific 
antagonists that retain high affinity at hFFA2-DREADD. The complete selectivity of the 
antagonists CATPB and GLPG0974 for the human orthologue of FFA2 was also useful in 
that neither of these had any effect, either directly when added alone or in capacity to block 
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the effects of C3, in tissues from wild type mice. This contrasts with the muscarinic 
acetylcholine receptor DREADDs where standard antagonists such as atropine maintain high 
affinity at the modified receptor and also still bind to and block all subtypes of the muscarinic 
receptor family10. The capacity herein to define effects of SA as ‘on-target’  or ‘off-target’ is 
particularly attractive because small molecule ligands with modest potency at the ‘on-target’ 
site are frequently pleotropic in actions and it is well established that SCFAs can, for 
example, also act as epigenetic regulators. Indeed, in a recent study using isolated perfused 
rat colon as a model of colonic endocrine secretion Christiansen et al., suggested that effects 
of SCFAs on release of GLP-1 were not mediated by either FFA2 or FFA338. As a number of 
other GPCRs are known to have antagonist ligands that are highly species orthologue 
selective then the proof-of-concept developed herein may well be appropriate to define both 
‘on-target’ and ‘off-target’ effects of activators of other poorly characterised GPCRs by 
developing equivalent transgenic mouse lines.  
A role of FFA2 in GLP-1 release from enteroendocrine cells was further supported by 
our in vivo studies where GLP-1 levels in the portal vein were seen to be increased following 
intra-colonic administration of SA in hFFA2-DREADD mice. Such a response was not 
produced in control mice. This not only confirmed a role for FFA2 in the regulation of GLP-1 
release from the gut but importantly it established the general utility of the DREADD-model 
to study the biology of FFA2 in live animals. This general principle was further extended by 
investigation of a potential role of FFA2 in the regulation of gut transit. Earlier in vitro and in 
vivo studies reported conflicting findings where SFCAs, possibly acting at FFA2, regulated 
gut transit either in a positive32 or negative33 manner. By administration of SA in the drinking 
water we were able to resolve these contradictory studies by showing that SA accelerated gut 
transit in a manner that was completely dependent on the expression of the hFFA2-
DREADD-HA receptor.  
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Although somewhat less contentious in terms of the identity of the receptor(s) 
involved39-41, equivalent studies with tissue from the knockin mouse lines also provided 
unequivocal evidence that FFA2 is the receptor responsible for SCFA-mediated anti-lipolytic 
responses in white fat epididymal cells. Our previous studies established that SCFAs mediate 
anti-lipolytic effects through Gi-signalling and GLP-1 release through Gq/11-signalling
26. 
Linking these previous findings with the current studies determines that these physiological 
effects of SCFAs are both mediated via FFA2 and, more interestingly, we can conclude that 
FFA2 recruits distinct G proteins in a tissue-dependent fashion to drive specific physiological 
responses26. The promiscuous G protein-coupling capability of FFA2 that has also been 
observed in previous in vitro studies21 may therefore illustrate a natural flexibility to recruit 
different G proteins to drive selected physiological responses in different settings.  
In our study we have not only used hFFA2-DREADD  to define novel biology of 
FFA2 but also provided evidence for the general application of other DREADD knockin mice 
to define the function of GPCRs for which selective ligands are not available. This approach 
also provides a means of testing the physiological roles and potential therapeutic outcomes of 
selectively activating the target GPCR. In this way, using FFA2 as an exemplar receptor, we 
have illustrated the broader potential of this approach to investigate both GPCR biology and 
drug target validation.  
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Figure Legends 
Figure 1 G protein interaction patterns and signal regulation by specific agonists of 
hFFA2 and hFFA2-DREADD are indistinguishable  
The ability of C3 (a) and sorbic acid (SA) (b), each at 10 mM, to promote interactions 
between either hFFA2 (a) or hFFA2-DREADD (b) and a range of mammalian G protein  
subunits was assessed using a BRET-based GRK2 biosensor assay22. Potency and capacity of 
C3 (circle) or SA (triangle) to inhibit forskolin-stimulated cAMP levels in Flp-InTM T-
RExTM 293 cells induced to express hFFA2 (c) or hFFA2-DREADD (d) were measured. 
Equivalent studies also measured the potency and capacity of C3 and SA to promote 
accumulation of inositol monophosphates (IP1) in Flp-InTM T-RExTM 293 cells induced to 
express hFFA2 (e) or hFFA2-DREADD (f). Data represent the mean ± SD (a, b) or SEM (c – 
f) (n = 2 b; n = 3 a; n = 6 c - f). 
 
Figure 2 Initial characterisation of hFFA2-DREADD-HA expressing mice 
mRNA isolated from the indicated tissues of C57BL/6 mice (a, d), those homozygous for 
expression of  hFFA2-DREADD-HA (b, d) or the ‘MINUS-CRE’ line (c, d) was used in 
qRT-PCR studies with primers designed to recognise specifically mouse FFA2 (a) or hFFA2-
DREADD-HA (b, c). Similar studies used primers to detect mouse FFA3 (d). Data are 
presented as 1/ Ct and are derived from studies conducted on mRNA isolated from at least 
two mice. Data represent the mean ± SEM. 
 
Figure 3  Immunocytochemical detection of expression of hFFA2-DREADD-HA 
Sections from colonic tissue isolated from C57BL/6 and hFFA2-DREADD-HA expressing 
mice were immunostained with an enteroendocrine cell marker (anti-chromogranin A, green) 
and an antibody for the hFFA2-DREADD-HA protein (anti-HA, red). Images were acquired 
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at 20x and 63x objectives and scale bars are shown. Solid arrows represent examples of cells 
that display co-localisation of anti-chromogranin A and anti-HA antibodies; dotted arrows 
represent examples that display localisation of only anti-chromogranin A, but not anti-HA 
antibodies. Representative images are shown.  
 
Figure 4 Activation of hFFA2-DREADD-HA promotes release of GLP-1 
Colonic crypt-containing preparations were generated from C57BL/6, and both 
MINUS-CRE and hFFA2-DREADD-HA expressing mice. Treatment with IBMX strongly 
promoted release of GLP-1, and to similar extents in each case (a). The ability of C3 or 
sorbic acid (SA) to promote release of GLP-1 was assessed in preparations from C57BL/6 
(b), hFFA2-DREADD-HA (c) and MINUS-CRE (d) mice. Results are presented relative to 
the effect of IBMX (100 M). The ability of CATPB (e) and GLPG0974 (f) to inhibit GLP-1 
secretion induced by SA (e, f) in colonic crypts derived from hFFA2-DREADD-HA 
expressing mice is shown (e, f). Data represent the mean ± SEM (n = 3-5). *** P < 0.001, 
two-way ANOVA followed by Bonferroni post hoc test (a). * P < 0.05, ** P< 0.01, *** P < 
0.001, for significance versus vehicle data; $$$ P < 0.001, one-way ANOVA followed by 
Bonferroni post hoc test (b - f). Intact colonic preparations from C57BL/6 (g) or hFFA2-
DREADD-HA (h) mice were mounted in a tissue chamber and following perfusion with 
buffer alone, either C3 (10 mM) (g) or SA (1 mM) (h, circles) was perfused at the time 
indicated by the arrow. GLPG0974 (10 M) was perfused for 15 mins before addition of SA 
and maintained throughout the exposure to SA (h, squares). Data represent the mean ± SEM 
(n = 3-4). * P < 0.05, ** P< 0.01, for significance versus vehicle (mean between values 
measured at 5, 10 and 15 min); one-way ANOVA followed by Bonferroni post hoc test (g, 
h).  $ P < 0.05, $$ P< 0.01, for significance of SA versus SA in the presence of GLPG0974; 
two- way ANOVA followed by Bonferroni post hoc test (h). 
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Figure 5 Activation of hFFA2-DREADD-HA is anti-lipolytic 
Adipocytes were isolated and differentiated from epididymal fat taken from C57BL/6, 
hFFA2-DREADD-HA and MINUS-CRE mice. Oil Red O staining was used to measure 
relative levels of triglycerides (a). Varying concentrations of the -adrenoceptor agonist 
isoproterenol (isopr.) stimulated lipolysis in these adipocytes (b). The ability of either C3 or 
sorbic acid (SA) to inhibit isoproterenol-mediated stimulation of lipolysis was assessed in 
adipocytes from C57BL/6 (c),  hFFA2-DREADD-HA (d) and MINUS-CRE (e) mice. The 
antagonists CATPB (f) and GLPG0974 (g) reversed SA-mediated anti-lipolytic effects in 
adipocytes from mice expressing hFFA2-DREADD-HA. For both CATPB and GLPG0974 
this was produced in a concentration-dependent fashion. Data are expressed as the percentage 
of lipolysis taking as 100% the maximal effect of isoproterenol 1 M (b) or 5 nM (c - g). 
Results represent the mean ± SEM (n = 3-6). ** P < 0.01, *** P < 0.001, for significance 
versus isoproterenol-induced response; $$ P < 0.01, $$$ P < 0.001, for significance versus SA-
induced response; one-way ANOVA followed by Bonferroni post hoc test (a, c - g).  
 
Figure 6 In vivo activation of hFFA2-DREADD-HA reveals roles in GLP-1 release and 
gut transit  
(a-c) Total GLP-1 was assessed in portal vein blood samples collected 10 min after an intra-
colonic injection of saline (vehicle), C3 (150 mM) or sorbic acid (SA, 15 mM) in isofurane-
anaesthetized C57BL/6 (a), MINUS-CRE (b) and hFFA2-DREADD-HA (c) mice. Data 
represent the mean ± SEM (n = 6-12). ** P < 0.01, **** P< 0.0001, two-tailed t test (a and 
c); one-way ANOVA followed by Bonferroni post hoc test (b). 
(d-e) In vivo gastrointestinal transit was assessed in either C57BL/6 (d)  or hFFA2-
DREADD-HA (e) mice that were provided with free access to water, C3 (150 mM) or SA (15 
mM) for 4 days after an intial acclimitisation phase. On the final day, mice were gavaged and 
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GI transit was measured. Data represent the mean ± SEM (n = 4-7). Significant reduction of 
GI transit time was observed in C57BL/6 with C3 (d) and in hFFA2-DREADD-HA with SA 
(15 mM) (e). * P < 0.05, ***P < 0.001 (one-way ANOVA followed by Bonferroni post-test  
for multiple comparisons (d) and two-tailed t test (e)).  Note: the data presented in this d and 
e is the cumulative data of the individual mice that are presented in Supplementary Figure 8.  
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Legends For Supplementary Figures 
Supplementary Figure 1 
BRET biosensor reports G protein interaction patterns by measuring interactions 
between G and G subunits.   
Cells were transfected with a BRET biosensor consisting of donor RlucII tagged Gα-subunits 
and an acceptor GFP10-Gγ1 subunit together with G1 and either hFFA2 (a), hFFA2-
DREADD (b) or human M3-muscarinic acetylcholine receptor (hM3-R) (c).  The changes in 
BRET signal following receptor stimulation with either C3 (10 mM), sorbic acid (SA) (10 
mM) or carbachol (100 µM) are shown.  Data represent the mean ± SD (n = 3).   
 
Supplementary Figure 2  
-arrestin 2 recruitment patterns in hFFA2 and FFFA2-DREADD are indistinguishable 
The potency and capacity of C3 or SA to promote interactions between eYFP-tagged forms 
of hFFA2 (a) or hFFA2-DREADD (b) and NanoLuc® luciferase-tagged -arrestin-2 was 
measured in HEK293T cells transfected transiently to co-express the arrestin and appropriate 
receptor variant. Data represent the mean ± SEM (n = 5). 
 
Supplementary Figure 3 
The hFFA2 antagonists CATPB and GLPG0974 each have high affinity for both hFFA2 
and hFFA2-DREADD 
The ability of varying concentrations of [3H]GLPG0974 to bind specifically to hFFA2-
DREADD in membranes from Flp-InTM T-RExTM 293 cells induced to express this construct 
is shown (a). Non-specific binding was defined in parallel experiments that also contained 10 
M GLPG0974. The ability of varying concentrations of CATPB (squares) and GLPG0974 
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(diamonds) to compete with [3H]GLPG0974 to bind to hFFA2 (b) or hFFA2-DREADD (c) 
is shown. The ability of CATPB (squares) and GLPG0974 (diamonds) to inhibit interactions 
between hFFA2-eYFP (d) or hFFA2-DREADD-eYFP (e) and β-arrestin-2 NanoLuc® 
luciferase induced by EC80 concentrations of C3 (2.5 mM) (d) or sorbic acid (SA) (0.63 mM) 
(e) was assessed. Data represent means ± SEM (n = 3-4). 
 
Supplementary Figure 4 
Generation of hFFA2-DREADD-HA expressing mice 
Transgenic knockin mice were generated by insertion of a loxP-stop-loxP cassette containing 
the hFFA2-DREADD-HA sequence in the coding exon of Ffar2. After homologous 
recombination and insertion of ES into blastocysts, the generated chimeric mice were bred 
with C57BL/6 or Cre-recombinase expressing mice in order to obtain MINUS-CRE mice and 
mice constitutively expressing the hFFA2-DREADD-HA construct. 
 
Supplementary Figure 5 
Expression of hFFA2-DREADD-HA is not detectable in MINUS-CRE mice 
Studies akin to Figure 3 were performed on sections from colonic tissue isolated from mice  
expressing hFFA2-DREADD-HA and the MINUS-CRE line (a). Staining for each of anti-
HA and anti-chromogranin A is displayed in representative images. 
Similar studies were performed on sections of duodenal tissue (b). Submucosal clusters of 
HA-positive cells were detected in tissue from the hFFA2-DREADD-HA expressing line but 
no co-localisation with chromogranin A was observed. No anti-HA staining was detected in 
tissue from  either C57BL/6 or the MINUS-CRE animals. 
 
Supplementary Figure 6 
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GLPG0974 and CATPB are unable to block effects of C3 in colonic crypts from 
C57BL/6 mice 
The antagonists CATPB and GLPG0974 were unable to reverse the effect of C3 on GLP-1 
secretion in colonic crypts derived from C57BL/6 mice. Results are presented relative to the 
effect of IBMX (100 M). Data represent the mean ± SEM (n = 3-4). *P < 0.05, for 
significance versus vehicle data; one-way ANOVA followed by Bonferroni post hoc test. 
 
Supplementary Figure 7 
Anti-lipolytic effect of sorbic acid at FFA2 
Concentration-response curves for the anti-lipolytic effect of sorbic acid on isoproterenol-
induced lipolysis (using 5 nM isoproterenol) in adipocytes derived from hFFA2-DREADD-
HA expressing mice. Results are presented as % lipolysis with the effect of isoproterenol 5 
nM recorded as 100%. Data represent the mean ± SEM (n = 5). 
 
Supplementary Figure 8 
Human selective FFA2 antagonists GLPG0974 and CATPB  fail to block C3 responses 
in adipocytes derived from C57BL/6 mice 
The hFFA2 antagonists CATPB (a) and GLPG0974 (b) were unable to reverse the effect of 
C3 on isoproterenol-induced lipolysis (isopr.) in adipocytes derived from C57BL/6 mice. 
Results are presented as % lipolysis with the effect of isoproterenol 5 nM recorded as 100%. 
Data represent the mean ± SEM (n = 3-4). *** P < 0.001, for significance versus 
isoproterenol-induced response; one-way ANOVA followed by Bonferroni post hoc test. 
 
Supplementary Figure 9 
Defining the Gi- and Gq-mediated responses to FFA2 in colonic crypts and adipocytes 
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The anti-lipolytic (a) and the GLP-1 response (b)  of sorbic acid (SA) in adipocytes or 
colonic crypts respectively, derived from hFFA2-DREADD-HA mice following pretreatment 
with vehicle, pertussis toxin (PTX)(to inactivate Gi) or the Gq-inhibitor FR900359. Results 
are presented as % lipolysis with the effect of isoproterenol 5 nM recorded as 100% (a) or  
relative to the effect of IBMX (100 M) (b). Data represent the mean ± SEM (n = 3-4). *P < 
0.05, for significance versus vehicle data (b); *** P < 0.001, for significance versus 
isoproterenol-induced response (a); one-way ANOVA followed by Bonferroni post hoc test. 
 
Supplementary Figure 10 
In vivo activation  of FFA2-DREADD reveals a role for FFA2 in gut transit 
In vivo gastrointestinal transit was assessed in either individual C57BL/6 (a, b, c) or hFFA2-
DREADD-HA (d, e) mice that were provided with free access to water (black bars), C3 (150 
mM) (grey bars) or sorbic acid (SA, 15 mM) (red bars) for 4 days after the acclimisation 
phase. Gut transit time of individual animals during acclimitisation phase (open bars). Note 
that these mice are used in the cumulative data shown in Figures 6d and e. 
 
